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Activation of AMP-activated protein kinase (AMPK) is
thought to convey many of the beneficial effects of
exercise via its inhibitory effect on acetyl-CoA
carboxylase 2 (ACC2) and promotion of fatty acid
oxidation. Hence, AMPK and ACC have become
major drug targets for weight loss and improved
insulin action. However, it remains unclear whether
or how activation of the fatty acid oxidation pathway
without a concomitant increase in energy expendi-
ture could be beneficial. Here, we have used
either pharmacological (administration of the AMPK
agonist 5
0
aminoimidazole-4-carboxamide-riboside)
or genetic means (mutation of the ACC2 gene in
mice) to manipulate fatty acid oxidation to determine
whether this is sufficient to promote leanness. Both
of these strategies increased whole-body fatty acid
oxidation without altering energy expenditure or
adiposity. We conclude that negative energy balance
is a prerequisite for weight reduction, and increased
fatty acid oxidation per se has little, if any, effect to
reduce adiposity.
INTRODUCTION
Obesity is linked to a number of metabolic diseases, such as
type 2 diabetes (T2D) and cardiovascular disease. Energy imbal-
ance, due to either reduced energy expenditure or increased
energy consumption, is the ultimate cause of obesity, with
excess nutrients being channeled into lipid depots. Although
adipose tissue is an ideal energy store over a certain ideal
body weight range, excess lipid is thought to contribute to
disease either via modulating the circulating adipokine profile
or by directly inducing damage in nonadipose tissues (lipotoxic-70 Cell Metabolism 11, 70–76, January 6, 2010 ª2010 Elsevier Inc.ity). In view of the poor success rate of lifestyle change in
managing human obesity, alternate solutions have been sought.
Impaired mitochondrial lipid metabolism has been linked to
metabolic disease (Savage et al., 2007). Mitochondria are
the major site for fatty acid oxidation (FAO), and defects in
this process may contribute to nonoxidative utilization of fatty
acids, such as triglyceride storage or conversion to lipotoxic
intermediates, both of which may increase adiposity and meta-
bolic disease. A decline in mitochondrial function has been
observed both during aging (Petersen et al., 2003) and in indi-
viduals with T2D (Kelley et al., 2002), suggesting that increasing
FAO may prevent lipid storage and improve metabolism.
A major caveat is that, thermodynamically, the only way to
achieve net weight loss, assuming that energy intake remains
constant, is to increase energy usage or decrease energy effi-
ciency by diverting metabolic energy to heat. Normally, electron
transport via the mitochondrial electron transport chain (ETC) is
tightly coupled to ATP synthesis, so increased oxidation of
nutrients would require increased ATP turnover. In the absence
of exercise or other forms of ATP hydrolysis, one way to
circumvent an oversupply of fuel substrates is to uncouple the
mitochondrial ETC from ATP production. Despite an obvious
thermodynamic requirement for increased energy expenditure
to promote leanness, it is still widely held that increased muscle
mitochondrial FAO per se is sufficient to reduce whole-body
adiposity.
AMPK-activated protein kinase (AMPK) regulates mitochon-
drial FAO by phosphorylating and inhibiting the activity of the
mitochondrial enzyme ACC2, leading to reduced malonyl-CoA
production. This leads to derepression of CPT1 activity and
increased long-chain FA entry into mitochondria. Treatment of
rodents with AMPK agonists is associated with leanness (Narkar
et al., 2008), and deletion of the ACC2 gene in mice has been
reported to result in increased FAO coupled with elevated
whole-body energy expenditure (Choi et al., 2007) and a marked
reduction in whole-body adiposity (Abu-Elheiga et al., 2001).
These studies support the notion that increased flux of FA into
mitochondria is sufficient to trigger increased whole-body
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lations trigger increased energy expenditure remains uncertain.
In the current report, we have re-examined the relationship
between increased fatty acid oxidation and reduced adiposity
by using both pharmacologic and genetic approaches. Our
results do not support the hypothesis that increased fatty acid
oxidation causes leanness. Rather, as predicted (Randle et al.,
1963), increasing the flux of FA into mitochondria without
a concomitant increase in energy demand resulted in a shift in
substrate oxidation from glucose and other fuels to FA, with no
net change in energy balance.
RESULTS
FAO Is Independent of Energy Expenditure
To assess whether increased FAO is associated with increased
energy expenditure, we treated rats with a single dose of
the AMPK activator 5
0
aminoimidazole-4-carboxamide-riboside
(AICAR) (250 mg/kg subcutaneous injection). AICAR increased
ACC2 phosphorylation, decreased malonyl-CoA levels by 55%
within 60 min of injection (Figures 1A and 1B), and increased
whole-body FAO, as shown by a drop in the respiratory
exchange ratio (RER) (Figure 1C), without any change in energy
expenditure (VO2) in the 10 hr following dosing (Figure 1D).
This suggests that there was a reciprocal decrease in the oxida-
tion of other substrates. To test this, we treated isolated EDL
muscles with AICAR (2 mM) ex vivo in the presence of either
14C-palmitate or 14C-glucose tracers. Consistent with the
in vivo data, AICAR increased palmitate oxidation (+31%, p <
0.001; Figure 1E) at the expense of glucose oxidation (30%,
p < 0.01; Figure 1F). This substrate-switching effect of AICAR
was due to increased fat oxidation rather than impaired glucose
availability or glycolysis because plasma lactate levels were
elevated 30 min after AICAR treatment in vivo (2.4 ± 0.3 versus
1.5 ± 0.3 mM, AICAR versus control, p < 0.05) and in the media
after palmitate oxidation (27.5 ± 1.3 versus 23.2 ± 1.6 mmol
lactate released/g EDL, AICAR versus control, p < 0.05).
As a control, rats were treated with the mitochondrial uncou-
pler dinitrophenol (DNP) (30 mg/kg oral administration). DNP
increased ACC2 phosphorylation, reduced cellular malonyl-
CoA levels by 32% (Figures 1A and 1B), increased FAO to
a similar extent as AICAR, and increased VO2 (Figures 1C and
1D). As predicted, in ex vivo experiments, DNP (0.5 mM) caused
a significant increase in energy demand and increased the
oxidation of both palmitate (+62%, p < 0.01; Figure 1G) and
glucose (+77%, p < 0.01; Figure 1H). We observed similar results
in rats fed a high-fat diet (HFD) for 21 days; AICAR and DNP
increased FAO, whereas only DNP increased VO2 (Figures 1I
and 1J).
Because activation of AMPK with AICAR did not increase
energy expenditure in either chow or HFD rats, it is unlikely that
this treatment would result in reduced body weight and/or
adiposity. Consistent with this, chronic treatment with AICAR
(250 mg/kg subcutaneous injection for 10 days) did not result in
any difference in body weight gain, food intake, fat mass, or
whole-body VO2 and RER (Figure S1 available online). As pre-
dicted (Winder et al., 2000), chronic AICAR increased the activity
of several oxidative enzymes and lipid metabolic enzymes in
muscle, consistent with increased muscle mitochondrial biogen-Cesis (Figure S2). Though we cannot exclude that longer-term acti-
vation of AMPK may drive changes in body composition and
energy metabolism via a separate AMPK target, such as SIRT1
and/or PGC-1a (Canto et al., 2009; Ja¨ger et al., 2007), our studies
do not support a major role for AMPK-mediated changes in
FAO via ACC inhibition in reduced adiposity. To determine the
effect of prolonged FAO on leanness and energy expenditure
independently of changes in mitochondrial capacity, we created
a mouse model of chronic FAO by deleting the ACC2 gene.
Preservation of Energy Neutrality despite Chronic FAO
We created ACC2-deficient mice on a pure C57BL/6 back-
ground. We flanked exon 12 of the ACC2 gene, encoding a crit-
ical region of the biotin carboxylase motif, with loxP sites and
crossed these mice onto a cre-deleter strain to remove exon
12 and introduce an early stop codon, rendering the ACC2
protein inactive (Figure 2A). Cre was bred out, and the resulting
mice were confirmed to be deficient in ACC2 by Southern blot
(data not shown), PCR (Figure 2B), and western blotting
(Figure 2C). Loss of ACC2 resulted in decreased malonyl-CoA
levels in skeletal and cardiac muscle, where ACC2 is the
predominant isoform (Figure 2D), and a 57% increase in FAO
in isolated soleus muscle (Figure 2E).
The functional consequences of ACC2 deletion on whole-
body metabolic parameters were then studied in WT and
ACC2/ littermates. ACC2/ mice had increased (p < 0.05)
whole-body FAO in the dark (0.87 ± 0.02 versus 0.92 ± 0.01,
ACC2/ versus WT) cycle and a trend for increased FAO during
the light cycle (0.85 ± 0.01 versus 0.88 ± 0.02, ACC2/ versus
WT) (Figure 3A); however, this was not accompanied by a change
in energy expenditure (WT light 34.2 ± 0.8 and dark 41.9 ± 1.6;
KO light 33.6 ± 0.7 and dark 42.2 ± 0.8 ml O2/kg/hr/100)
(Figure 3B). Despite preferential oxidation of FAs in ACC2/
mice compared to WT controls, we observed no difference in
body weight (Figure 3C) or adiposity between the two groups
(Figures 3D and 3E). Although there was no change in serum
lactate between genotypes (data not shown), muscle glycogen
stores were elevated, and the utilization of glucose for lipid
synthesis was increased in the ACC2/ mice, providing
evidence that the excess available glucose was being used non-
oxidatively (Figures 3F and 3G). Because there was no increase
in total TAG accumulation in liver or muscle (Figure 3H), the
increased amount of lipid being synthesized was likely being
used to support FAO. These data confirm our acute experiments
with AICAR in Figure 1 and show that long-term changes in FAO
are not linked to significant alterations in energy expenditure and
adiposity.
To explore whether the chronic elevation in FAO observed with
ACC2 deletion could prevent the metabolic defects induced by
an HFD, we challenged WT and ACC2/ mice with 36 days of
high-fat feeding. During this feeding regime, both genotypes
consumed similar quantities of food (Figure 4A), gained a similar
amount of body weight (Figure 4B), and exhibited similar fat
deposition in three separate adipose depots (Figure 4C). There
was also no indication that ACC2/ mice were protected from
HFD-induced insulin resistance, as they displayed similar
glucose and insulin tolerance as WT mice did (Figures 4D and
S3), and they had similar rates of glucose disposal into skeletal
muscle during the glucose tolerance test (Figure 4E) with similarell Metabolism 11, 70–76, January 6, 2010 ª2010 Elsevier Inc. 71
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Figure 1. AMPK Activation Drives FAO, but Not Energy Expenditure
Rats were acclimatized overnight and at 10 AM dosed with vehicle (saline), AICAR (250 mg/kg), or DNP (30 mg/kg).
(A) Avidin pulldown from skeletal muscle. ACC phosphorylation and expression 60 min after treatment. Pyruvate carboxylase (PC) is shown as a loading control
for the pulldown.
(B) Malonyl-CoA levels in skeletal muscle described in (A).
(C and D) Indirect calorimetry measurement of RER and VO2 before and after treatment with saline, DNP, or AICAR. Values indicated in the figure represent the
average of the 10 hr following dosing.
(E–H) EDL muscle strips were isolated and incubated ex vivo in KHB media with 5 mM glucose and 0.5 mM palmitate and either AICAR (2 mM) or DNP (0.5 mM).
Rates of FA and glucose oxidation were measured as described in Experimental Procedures.
(I and J) Indirect calorimetry measurement of RER and VO2 before and after treatment with saline, DNP, or AICAR in rats fed a high-fat diet for 21 days. Values
indicated in the figure represent the average of the 10 hr following dosing.
All results are displayed as means ± SEM. n > 5 and *p < 0.05 for the 10 hr period following dosing.
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Altering Fat Oxidation Remodels Glucose Metabolisminsulin levels to control mice (Figure 4F). Collectively, these find-
ings suggest that, despite the fact that ACC2/ mice display
increased lipid oxidation, they are not resistant to weight gain
or insulin resistance caused by 36 days of an HFD.72 Cell Metabolism 11, 70–76, January 6, 2010 ª2010 Elsevier Inc.DISCUSSION
Body weight and fat mass in mammals are highly robust param-
eters. Fat mass is very well defended, rendering many lifestyle
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Figure 2. Confirmation of ACC2 Deletion and
Phenotype
(A) Exon 12 encodes an essential region of the biotin
carboxylase motif and was targeted for deletion. Exon
12 was flanked with loxP sites and subsequently bred
with mice expressing Cre recombinase driven by the
early acting PGK promoter. Cre-mediated recombination
removes exon 12, the Neomycin selection cassette, and
causes a frameshift mutation and an early stop codon.
The PGK-Cre allele was subsequently bred out. The
embryonic stem cells and all crosses were performed
with pure C57BL/6 lineage.
(B) PCR confirmation of exon 12 deletion as described in
Experimental Procedures.
(C) Protein confirmation of ACC2 deletion by monomeric
avidin pulldown (see Experimental Procedures). Mem-
branes were probed with streptavidin 800, and ACC2,
ACC1, and propionyl-CoA Carboxylase (PCC) enzymes
were identified based on molecular weight.
(D) Malonyl-CoA levels in skeletal and cardiac muscle of
WT and ACC2/ mice.
(E) FAO rates in isolated soleus muscle from WT and
ACC2/ mice. *p < 0.05.
Error bars are displayed as means ± SEM.
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apies. The hypothesis that manipulations that enhance fat
burning will reduce adiposity has provided novel avenues and
new hope for the treatment of obesity. Indeed there is a link
between AMPK activation and leanness (Lage et al., 2008; Nar-
kar et al., 2008). Currently, the precise mechanism linking AMPK
to leanness is unknown, as AMPK activity has both short and
long-term effects. On one hand, AMPK rapidly increases FAO,
primarily via its inhibition of ACC. On the other, its prolonged
activity regulates many other pathways, such as mitochondrial
biogenesis (Bergeron et al., 2001; Winder et al., 2000), uncou-
pling protein expression (Narkar et al., 2008; Suwa et al.,
2003), GLUT4 expression (Winder et al., 2000), and the SIRT1
pathway (Canto et al., 2009). Hence, it is unclear whether
AMPK agonists promote leanness via the FAO pathway or an
alternate route (Figure 4G).
To address this question, we used pharmacological and
genetic manipulations in rodents to increase FAO upstream or
downstream of AMPK. We used AICAR to activate AMPK acutely
and chronically for 10 days. There was no change in body
composition, substrate utilization, or energy expenditure
following AICAR treatment at either time point, but there was
a clear stimulation of mitochondrial biogenesis in skeletal muscle
after 10 days. To test the effects of long-term changes in FAO
independently of AMPK, we directly targeted ACC2 in mice.
ACC2 inhibition led to reduced intracellular malonyl-CoA levels
and a concomitant increase in FAO in skeletal muscle without
any change in energy expenditure or adiposity. Rather, in both
acute and chronic settings, our data show that increased FAOCell Metabolism 1is offset by an alteration in the handling of other
macronutrients. Our findings are consistent with
previous studies using a nonselective ACC1/2
inhibitor in rats. This inhibitor decreased RER
over a 3 hr period without altering energy expen-
diture (Harwood et al., 2003). Second, reducedACC1/2 expression in rat liver and fat using antisense oligonucle-
otides was without effect on body weight (Savage et al., 2006).
This illustrates that increased FAO is insufficient to promote
energy expenditure or weight loss. Rather, the inherent flexibility
in the metabolic system compensates for enforced FAO by
altering carbohydrate metabolism. Such an effect is consistent
with the glucose-FA cycle first proposed by Randle (Randle
et al., 1963).
Our data are in contrast to a previous mouse model of ACC2
deficiency that displayed increased energy expenditure (Choi
et al., 2007) and a lean phenotype despite hyperphagia (Abu-
Elheiga et al., 2001). Although no mechanism for this effect has
been described, this mouse model has provided a major incen-
tive for targeting FAO as a treatment for human obesity. Why
have we been unable to observe changes in energy expenditure
or a lean phenotype in our ACC2/ mice, despite the fact that
they are metabolically similar in almost every other respect to
those reported previously (Abu-Elheiga et al., 2001; Choi et al.,
2007)? This is unlikely due to a more modest phenotype in our
animals because the increase in muscle and whole-body FAO
in the ACC2/ mice described here was more robust than
that reported previously (Abu-Elheiga et al., 2001; Choi et al.,
2007). There are a number of technical differences between
the two studies that may account for this difference. In our
studies, we constructed the ACC2 deletion on a genetically
pure C57BL/6 mouse background and performed our studies
using littermates to avoid founder effects. We also removed
the stem cell selection marker from the genome prior to study
to avoid potential artifacts, whereas this was not reported in1, 70–76, January 6, 2010 ª2010 Elsevier Inc. 73
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Figure 3. Chronic FAO Increases Glycogen
Storage, but Not Energy Expenditure
(A and B) Indirect calorimetry measurements were used
to determine RER and VO2 in male WT and ACC2
/
mice. *p < 0.05 for ACC2/ versus WT in the dark cycle.
(C–E) Body weight, body fat (by DEXA), and organ size
(by dissection) were measured in male littermate mice
18–22 weeks of age. n > 5.
(F) Glycogen content in hind limb skeletal muscle from
male WT and ACC2/ mice. n = 6. *p < 0.05.
(G) 14C-glucose incorporation into lipid in liver and white
adipose tissue in WT and ACC2/ mice following
a glucose load (1.5 g/kg). n = 4–7. *p < 0.05.
(H) Triacylglycerol content per g of liver tissue in WT and
ACC2/ mice. n = 4.
Error bars are displayed as means ± SEM.
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Altering Fat Oxidation Remodels Glucose Metabolismthe case of the previous studies (Abu-Elheiga et al., 2001), raising
the possibility that all tissues in that animal overexpressed an
enzyme involved in purine biosynthesis (HPRT). In addition, we
targeted an exon closer to the 50 end of the gene at an upstream
biotin carboxylase motif, and we could find no evidence for any
ACC2 polypeptide expressed in tissues from our animals.
Finally, one cannot ignore the fact that, of 2000 knockout
mouse models examined, 30% exhibit a lean phenotype, raising
the possibility that either 30% of all genes independently regu-
late leanness or other processes involved in genetic engineering
and selection somehow contribute to leanness (Reed et al.,
2008). This, combined with the fact that our ACC2/ mice phe-
nocopy long-term administration of AICAR in rats, provides
strong support for the theory that was advanced by Randle
nearly 50 years ago—that energy demand drives energy expen-
diture and that different substrates compete for entry into the
energy utilization pathway in a mutually exclusive manner. Our
results provide new evidence to indicate that FAO and energy
expenditure are not coupled, and thus the belief that FAO drives
leanness is likely incorrect or, at least, an oversimplification. The
implications of these findings are considerable, particularly for
those investing effort to develop ACC2 inhibitors for the treat-
ment of obesity and type 2 diabetes (Corbett, 2009).74 Cell Metabolism 11, 70–76, January 6, 2010 ª2010 Elsevier Inc.Excess adiposity and lipid accumulation in
nonadipose tissues are linked to insulin resis-
tance (Savage et al., 2007). However, the effect
of increasing FAO on insulin sensitivity is contro-
versial in that some studies indicate that
enhancing FAO protects against HFD-induced
insulin resistance (Bruce et al., 2009), whereas
other studies show that excessive FAO in fact
promotes insulin resistance (Koves et al.,
2008). In our study, we were unable to observe
any protective effect of increased FAO against
HFD-induced insulin resistance.
Based on the present study, it is unlikely that
increasing lipid oxidation alone is sufficient
to cause leanness. In view of the fact that
increased FAO was considered one of the major
mechanisms of AMPK in fat reduction and
leanness, this leaves open the possibility that
the adipose-lowering effects of chronic AMPKactivation are mediated via an alternate pathway, such as
increased mitochondrial biogenesis or increased expression of
uncoupling proteins. Hence, this study supports the traditional
view of energy homeostasis, which is that, under normal condi-
tions of thermoneutrality, body mass is principally controlled
by the balance between food consumption and ATP hydrolysis
and that coercing the animal to metabolize one nutrient in
favor of another, as in the case of the ACC2/ mouse, is
compensated for simply by downregulating the use of alternate
fuels, with the end result being no change in net energy balance.
EXPERIMENTAL PROCEDURES
Materials
Antibodies against ACC and phospho-S79 ACC were from Cell Signaling
(Beverly, MA). DNP was from Sigma, and AICAR was from Toronto Research
Chemicals. Monomeric avidin beads were from Pierce (Rockford, IL). Strepta-
vidin-conjugated IRDye-800 was from Rockland Chemicals (Gilbertsville, PA).
Animals
Food and water were provided ad libitum until the date of study, and all animal
care was in compliance with the Australian National Health and Medical
Research Council guidelines, as well as institutional guidelines at Garvan.
The high- and low-fat diets (45% and 8% kcal as fat, respectively) used are
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Gain and Insulin Sensitivity with 36 Days of High-
Fat Feeding
(A–C) Food intake, body weight gain, and fat pad weights
were measured over 36 days of high-fat feeding.
(D) Glucose tolerance test of 16-week-old male WT and
ACC2/ mice fed a chow diet or high-fat diet. n = 5–7
per group.
(E) Skeletal muscle insulin resistance was determined by
measuring glucose disposal into skeletal muscle during
the glucose tolerance test as described in Experimental
Procedures,
(F) Insulin levels were not altered between WT and
ACC2/ mice fed either a chow or high-fat diet.
Error bars are displayed as means ± SEM.
Cell Metabolism
Altering Fat Oxidation Remodels Glucose Metabolismdescribed previously (Bruce et al., 2009). Animals were maintained on a 12/12
light/dark schedule such that lights go out at 7 PM and on at 7 AM.
Generation of ACC2 Floxed Mice
The ACC2 gene has 52 exons. We targeted exon 12 because its deletion will
destroy the biotin carboxylase motif and will result in a frameshift mutation
and an early stop codon. Ozgene Pty Ltd. (Murdoch, Australia) was employed
to develop these mice. They designed the ACC2-targeting vector FLSniper in
three fragments—the 30 arm, the 50 arm, and the loxP arm—by PCR using
PGK-Neo-pA-SD-IS as the selection cassette. A BglII site was introduced in
the 50 loxP site and was used for targeting confirmation by Southern blotting.
The targeting vector was used for homologous recombination by electropora-
tion in Bruce4 embryonic stem (ES) cells. ACC2-targeted ES cell clones were
identified by PCR and Southern blot hybridization using 50 and 30 flanking
probes. Screening with the endogenous probe revealed a 13.8 kb wild-type
band, a 7.1 kb targeted band, and a 2.9 kb fragment when the floxed region
was deleted by Cre-recombinase (data not shown). The ES cells carrying the
correct mutation were injected into BALB/c blastocysts and implanted into
foster mothers. Chimeric progeny were bred with C57/BL6 mice to obtain
germline founders. These were then bred with heterozygous Cre-deleter
mice on a BL/6 background (ROSA locus knockin driven by a PGK promoter),
and genotyping of progeny was performed by Southern blot or PCR (Fig-
ure 2B). The PCR primers for Cre were CCGGTCGATGCAACGAGTGAT and
ACCAGAGTCATCCTTAGCGCC. Primer sets to differentiate between ACC2
wild-type, heterozygous, and homozygous knockout were ACC2 common
forward primer AGGATTTGAACTCAGGTCATCAGGCTTGGC, wild-type
reverse primer GTACAGAAGCCGTATGTCCTTCAGTCGGTG, and knockout
reverse primer CCTGAGCCGAGTGCTGGGCACCGTTTAGAC. These three
primers were all used in the same PCR reaction and generated products of
750 bp for WT, 1091 bp for KO, and both 750 bp and 1091 bp for HET
(Figure 2B). Mice were maintained on a C57BL/6 background and bred with
our in-house C57BL/6 line. The Cre allele was bred out for all mice in this study.
Glucose and Insulin Tolerance Testing
Mice were fasted for 6 hr and were then injected intraperitoneally with glucose
(1.5 g/kg) or insulin (0.5 U/kg), and blood glucose levels were monitored over
time using an Accu-check II glucometer (Roche Diagnostics, Castle Hill,Cell Metabolism 1Australia). Clearance of 14C-glucose (10 mCi/animal) into
lipid and [3H]-2-DOG (10 mCi/animal) into glucose-6-phos-
pate during the glucose tolerance test were determined
using methods described previously (Bruce et al., 2009;
Cooney et al., 2004).
Avidin Pulldown
Protein lysates were prepared by homogenizing tissues in
NP-40 lysis buffer. 300 mg protein was incubated with
monomeric avidin beads overnight at 4C. The beads
were then washed, and the biotin-containing proteins
were eluted with 1 3 Laemmli buffer at 65C for 5 min.
Eluate was run on a 6% SDS-PAGE gel, transferred to
PVDF, and probed with streptavidin-conjugated IRDye800, and biotinylated proteins were detected on a LiCOR Odyssey Infrared
Scanner.
Enzyme Activity Measurements and Immunoblotting in Muscle
Measurement of the activity of oxidative enzymes and immunoblotting of
proteins involved in mitochondrial function and lipid metabolism were con-
ducted as described previously (Bruce et al., 2009; MacArthur et al., 2008).
Respirometry
Oxygen consumption rate (VO2) and respiratory exchange ratio (RER) were
measuredundera consistent environmental temperature (22C)usingan indirect
calorimetry system (Oxymax series, Columbus Instruments, Columbus, OH). For
mice, studies were commenced after 2 hr of acclimation to the metabolic
chamber using an air flow of 0.6 l/min. VO2 was measured in individual mice
at 27 min intervals during a 24 hr period. For the rat studies, the air flow was
1.5 l/min, and measurements were made at 15 min intervals. Animals were
placed in the chamber in the late afternoon and on the following morning were
dosed with vehicle, AICAR, or DNP at the doses detailed in the figure legends.
During the studies, both mice and rats had ad libitum access to food and water.
Ex Vivo Muscle Substrate Oxidation
Palmitate and glucose oxidation were determined in muscle strips as
described (Bruce et al., 2009; Hoy et al., 2007). In brief, whole soleus from
mice or EDL strips from rats were dissected tendon to tendon and placed in
a vial containing warmed (30–34C), pregassed (95% O2-5% CO2 [pH 7.4]),
modified Krebs-Henseleit buffer containing 4% FA-free BSA, 5 mM glucose,
and 0.5 mM palmitate, giving a palmitate:BSA molar ratio of 1:1. Following
a 30 min preincubation period, muscle strips were transferred to vials contain-
ing 0.5 mCi/ml of [1-14C] palmitate or 2 mCi/ml of [U-14C] glucose (GE Health-
care Life Sciences, Buckinghamshire, UK) for 60 min. At the completion of
this phase, the medium was acidified with 1 M HClO4, and evolved
14CO2
was captured in 1M NaOH.
Blood and Tissue Metabolites
Insulin was measured from whole blood by ELISA (Crystal Chem, Downers
Grove, IL). NEFAs were measured calorimetrically (WAKO diagnostics, Osaka1, 70–76, January 6, 2010 ª2010 Elsevier Inc. 75
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Altering Fat Oxidation Remodels Glucose MetabolismJapan). TAG and glycogen contents were measured in tissues as described
previously (Bruce et al., 2009; Hoy et al., 2007). Malonyl-CoA was measured
from rat skeletal muscle 60 min after saline, DNP, or AICAR injection and
from wild-type or ACC2KO mice fasted for 12 hr. Malonyl-CoA was measured
by LC-MS/MS using a modification of the method described (Minkler et al.,
2006). Specific details of the malonyl-CoA assays can be found in the Supple-
mental Information.
Statistical Analyses
Data are expressed as means ± standard error. P values were calculated by
two-tailed Student’s t test or one-way ANOVA with Fisher’s PLSD post-hoc
test. Statistical significance was set at p < 0.05. All results are displayed as
means ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information include Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/
j.cmet.2009.11.008.
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